Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials

EuroIntervention 2017;12:1970-1977 published online November 2016. DOI: 10.4244/EIJ-D-16-00773

Georgios J. Vlachojannis
Georgios J. Vlachojannis1, MD, PhD; Serban Puricel2, MD; Masahiro Natsuaki3, MD; Takeshi Morimoto4, MD, PhD, MPH; Pieter C. Smits1*, MD, PhD; Takeshi Kimura5, MD; on behalf of the NEXT and COMPARE II investigators
1. Division of Cardiology, Maasstad Hospital, Rotterdam, The Netherlands; 2. Division of Cardiology, University of Fribourg, Fribourg, Switzerland; 3. Division of Cardiology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan; 4. Department of Clinical Ep

Aims: This study sought to investigate the safety and efficacy of a biolimus-eluting stent with biodegradable polymer (BP-BES) (Nobori; Terumo Corp.) compared to an everolimus-eluting ste

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

biodegradable polymerbiolimus-eluting stenteverolimus-eluting stentnoboripooled analysisxience
Coronary interventionsStents and scaffoldsTools, devices and techniques
Read next article
Clinical outcomes of bioresorbable versus durable polymer-coated everolimus-eluting stents in real-world complex patients

Latest news